Cell host & microbe
Cure8 research brief
Why This Matters
If gut bacteria transform methotrexate into a molecule that supports epithelial mitochondrial health and limits inflammation, that could partly explain why MTX works for some people with IBD and not others. Understanding this pathway could lead to microbiome-informed ways to predict or improve MTX response.
Who Should Pay Attention
Researchers studying IBD mechanisms or drug–microbiome interactions; clinicians interested in MTX variability in IBD; patients interested in how the gut microbiome may affect medication response.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This Cell Host & Microbe abstract reports that gut bacteria (notably Clostridium asparagiforme) metabolize methotrexate (MTX) via a microbial enzyme (CPDG2) to produce deoxyaminopteroic acid (DAMPA).
In cell and mouse experiments DAMPA activated STAT3 signaling in intestinal epithelial cells, supported mitochondrial health and mitophagy, and reduced intestinal inflammation. The authors also report lower CPDG2 gene abundance and reduced DAMPA-associated mitochondrial pathways in IBD samples, suggesting a microbiome link to variable MTX effects in IBD.
Key details The source is a journal abstract (Cell Host & Microbe) summarized on PubMed; the extraction is labeled “abstract,” so the brief is grounded in the provided abstract rather than a full paper.
The findings combine microbial biochemistry, cell signaling (STAT3), and mouse model experiments; human data reported are genomic/pathway observations (reduced CPDG2 abundance and suppressed DAMPA-enriched pathways) rather than clinical trial results.
Practical takeaways This research suggests that part of MTX’s effect in the gut may come from bacterial conversion of the drug into a metabolite (DAMPA) that influences epithelial mitochondrial function and inflammation. Differences in patients’ gut microbes (CPDG2 abundance) might help explain why MTX works for some people with IBD but not others.
These are mechanistic, preclinical and correlative human molecular findings—not evidence that changing treatment now will improve outcomes.
Keep In Mind
This classification is based on the journal abstract extracted on PubMed (structured content depth: abstract). The reported work includes cell and mouse experiments plus correlative human molecular data; it does not present clinical trial results showing changed patient outcomes.
The findings are mechanistic and hypothesis-generating; further clinical validation would be needed before changing patient care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCell host & microbe
AuthorsJuyeong Cho, Rebecca Danner, Woo Sung Kim +8 more
InstitutionDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA; Nutrition and Metabolism Graduate Program, University of Wisconsin-Madison, Madison, WI 53706, USA.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedNov 5, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of interests The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis.
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
Gut Microbiota-Driven Neuroimmune Crosstalk in Ulcerative Colitis: From Mechanisms to Therapeutic Implications
Understanding microbiota–neuroimmune interactions could explain why symptoms like urgency and pain persist in some people with UC and may point to new treatment strategies that go beyond conventional anti-inflammatory...
Blautia wexlerae ameliorates ulcerative colitis via metabolic remodeling of the gut microbiota.
The study links a specific gut microbe and its metabolite to reduced inflammation and improved barrier function in ulcerative colitis models and cohort comparisons, suggesting a potential new microbiome-targeted therapy...